AACR 2014 – EKF Molecular Highlights Ultra-Sensitive Cancer Mutation Detection Kits

26 Mar 2014
Share
PointMan™ DNA-enrichment kits offer unrivalled cancer gene detection in whole blood.


EKF Diagnostics, the global in vitro diagnostics business, will be present on Booth #438 at AACR 2014 (American Association of Cancer Research), 5-9th April, San Diego. EKF Molecular will exhibit its PointMan™ DNA-enrichment technology which enables ultra-sensitive and highly-specific cancer mutation detection unmatched by existing technologies.

PointMan™ is an extremely sensitive and selective tool based on real-time PCR technology offering the ability to enrich mutations from limited sample material. This is vital for a companion diagnostic particularly in the field of oncology, where availability of tumour biopsy tissue is restricted. In collaboration with Swansea University, EKF Molecular is currently investigating the ability of PointMan™ kits to enrich mutant DNA from a blood-based sample. Initial results have demonstrated the detection of gene mutations in blood from samples archived in the Wales Cancer Bank.

EKF Molecular has a growing range of products and technologies developed to meet an increasing demand for superior sensitivity and specificity in molecular diagnostics. PointMan DNA enrichment kits are available to detect a variety of mutations for cancer biomarkers including: BRAF, KRAS, EGFR, NRAS and JAK2. These genes are associated with skin melanoma, colorectal and lung cancers, as well as myeloma.

Request Info


Company website

EKF Diagnostics
profile photo

Lois Manton
Editorial Assistant